切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2019, Vol. 08 ›› Issue (03) : 121 -127. doi: 10.3877/cma.j.issn.2095-3216.2019.03.005

所属专题: 文献

论著

THSD7A与膜性肾病相关性的Meta分析
王静1, 乔玉峰2,(), 薛福平3, 金众鑫1, 王利华2   
  1. 1. 030001 山西医科大学
    2. 山西医科大学第二医院肾内科
    3. 030006 武警山西总队医院肾病科
  • 收稿日期:2018-12-02 出版日期:2019-06-28
  • 通信作者: 乔玉峰

Meta-analysis of the correlation between THSD7A and membranous nephropathy

Jing Wang1, Yufeng Qiao2,(), Fuping Xue3, Zhongxin Jin1, Lihua Wang2   

  1. 1. Shanxi Medical University, Taiyuan 030001
    2. Department of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan 030001
    3. Department of Nephrology, Shanxi Provincial Corps Hospital of Chinese People′s Armed Police Forces, Taiyuan 030006; Shanxi Province, China
  • Received:2018-12-02 Published:2019-06-28
  • Corresponding author: Yufeng Qiao
  • About author:
    Corresponding author: Qiao Yufeng, Email:
引用本文:

王静, 乔玉峰, 薛福平, 金众鑫, 王利华. THSD7A与膜性肾病相关性的Meta分析[J/OL]. 中华肾病研究电子杂志, 2019, 08(03): 121-127.

Jing Wang, Yufeng Qiao, Fuping Xue, Zhongxin Jin, Lihua Wang. Meta-analysis of the correlation between THSD7A and membranous nephropathy[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(03): 121-127.

目的

系统分析评价1型血小板反应蛋白7A域(thrombospondin type 1 domain-containing 7A, THSD7A)在膜性肾病(MN)中的表达及诊断意义。

方法

系统检索万方医学网、中国知网(CNKI)、医知网、中国生物医学文献数据库、PubMed数据库收录的中英文文献,同时手工检索纳入文献的参考文献。采用R软件和RevMan 5.3软件对MN患者中THSD7A的表达情况进行Meta分析。比较血清学检测和组织学检测THSD7A的阳性率;分析THSD7A分别在MN、原发性MN(IMN)和继发性MN(SMN)患者中的阳性率;分析THSD7A相关MN合并恶性肿瘤的阳性率;根据THSD7A阳性患者的人种进行亚组分析。

结果

共纳入11篇文献,总共4826例MN患者,发表偏倚漏斗图对称分布。其中5项研究同时进行血清学和组织学THSD7A阳性率检测,其阳性率差异没有统计学意义(OR=0.88, 95%CI: 0.62~1.25,P=0.48)。MN中THSD7A的阳性率为2.76%(95%CI:2.33%~3.28%);IMN中THSD7A的阳性率为2.94%(95%CI:2.19%~3.94%);SMN中THSD7A的阳性率为2.60%(95%CI:1.29%~5.27%)。亚组分析结果显示,黄种人中THSD7A相关MN阳性率为2.49%(95%CI:1.75%~3.54%),高加索人中THSD7A相关MN阳性率2.85%(95%CI:2.35%~3.47%),其阳性率差异没有统计学意义(I2=55.5%,P=0.13)。THSD7A相关MN患者合并恶性肿瘤的阳性率为9.19%(95%CI:4.68%~15.00%)。

结论

血清学和组织学检测THSD7A阳性率无统计学差异。IMN和SMN以及不同人种中THSD7A阳性率无明显差异。THSD7A相关MN患者合并恶性肿瘤的阳性率为9.19%。

Objective

To systematically analyze the expression of thrombospondin type 1 domain-containing 7A (THSD7A) and its diagnostic significance in membranous nephropathy (MN).

Methods

Both Chinese and English literatures were systematically searched included in Wanfang Med Online, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database, and PubMed. Meanwhile, references of the included literatures were also retrieved manually. Meta-analysis of the expression of THSD7A in MN patients was made with the R software and RevMan 5.3 software. The positive rates of THSD7A expression detected with serological and histological methods were compared. And the positive rates of THSD7A expression in MN, idiopathic MN (IMN), and secondary MN (SMN) patients were also compared. The prevalence of malignant tumors in the patients with THSD7A-associated MN was analyzed. Subgroup analysis was made according to the ethnicity of the patients with positive expression of THSD7A.

Results

A total of 11 articles were included with a total of 4826 MN patients. The funnel plot was symmetrically distributed. The positive rates of THSD7A expression detected by both serological and histological methods in 5 of the 11 studies were compared, with the difference of positive rates being not statistically significant (OR=0.88, 95%CI: 0.62-1.25, P=0.48). The positive rate of THSD7A was 2.76% (95%CI: 2.33%-3.28%) in MN, 2.94% (95%CI: 2.19%-3.94%) in IMN, and 2.60% (95%CI: 1.29%-5.27%) in SMN. The subgroup analysis showed that the prevalence of THSD7A-associated MN was 2.49% (95%CI: 1.75%-3.54%) in the yellow race, and 2.85% (95%CI: 2.35%-3.47%) in the Caucasians, the difference of which was not statistically significant (I2=55.5%, P=0.13). The prevalence of malignant tumors in the patients with THSD7A-associated MN was 9.19% (95%CI: 4.68%-15.00%).

Conclusion

There was no significant difference in the positive rate of THSD7A expression between the serology and histology methods. THSD7A was an indicator of both IMN and SMN, and its positive rate was not significantly different between different races. The prevalence of malignant tumors in the patients with THSD7A-associated MN was 9.19%.

表1 纳入研究的基本情况
表2 QUADAS文献质量评价
图1 血清学和组织学检测THSD7A的Meta分析森林图
图2 THSD7A相关MN阳性率的Meta分析森林图
图3 THSD7A相关IMN阳性率的Meta分析森林图
图4 THSD7A相关SMN阳性率的Meta分析森林图
图5 THSD7A相关MN阳性率在不同人种的Meta分析森林图
图6 THSD7A相关MN合并恶性肿瘤阳性率的Meta分析森林图
图7 本研究纳入文献的发表偏倚漏斗图
[1]
Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care [J]. Lancet, 2015, 385(9981): 1983-1992.
[2]
Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews [J]. BMC Med Res Methodol, 2003, 3(1): 25.
[3]
Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-1 domain-containing 7A in Chinese patients with idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(10): 1642-1651.
[4]
温丽颖,李绍梅,闫喆,等.M型磷脂酶A2受体及1型血小板反应蛋白7A域在成人原发性膜性肾病的表达及其意义[J].中华肾脏病杂志,2016,32(8):561-567.
[5]
Lin L, Wang WM, Pan XX, et al. Biomarkers to detect membranous nephropathy in Chinese patients [J]. Oncotarget, 2016, 7(42): 67868-67879.
[6]
Zhang D, Zou J, Zhang C, et al. Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-1 domain-containing 7A-associated idiopathic membranous nephropathy: a single center retrospective study from China [J]. Med Sci Monit, 2018, 24: 5076-5083.
[7]
Hayashi N, Okada K, Matsui Y, et al. Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy [J]. Nephrol Dial Transplant, 2017, 33(5): 832-840.
[8]
Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371(24): 2277-2287.
[9]
Iwakura T, Ohashi N, Kato A, et al. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy [J]. PLoS One, 2015, 10(9): e0138841.
[10]
L′Imperio V, Pieruzzi F, Sinico RA, et al. Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain [J]. J Nephrol, 2018, 31(4): 543-550.
[11]
Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study [J]. Mod Pathol, 2017, 31(4): 616-622.
[12]
Larsen CP, Cossey LN, Beck LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity [J]. Mod Pathol, 2016, 29(4): 421-426.
[13]
Hoxha E, Beck LH Jr, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy [J]. J Am Soc Nephrol, 2016, 28(2): 520-531.
[14]
Zhang X, Liu S, Tang L, et al. Analysis of pathological data of renal biopsy at one single center in China from 1987 to 2012 [J]. Chin Med J (Engl), 2014, 127(9): 1715-1720.
[15]
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
[16]
Beck LH Jr. PLA2R and THSD7A: disparate paths to the same disease [J]. J Am Soc Nephrol, 2017, 28(9): 2579-2589.
[17]
Seifert L, Hoxha E, Eichhoff AM, et al. The most N-terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-associated membranous nephropathy [J]. J Am Soc Nephrol, 2018, 29(5): 1536-1548.
[18]
Francis JM, Beck LH Jr, Salant DJ. Membranous nephropathy: a journey from bench to bedside [J]. Am J Kidney Dis, 2016, 68(1): 138-147.
[19]
Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN [J]. Ren Fail, 2018, 40(1): 306-313.
[20]
周广宇,刘锋,张文龙.M型磷脂酶A2受体基因单核苷酸多态性与膜性肾病的相关性[J].中华医学遗传学杂志,2013,30(6):706-710.
[21]
Stahl PR, Hoxha E, Wiech T, et al. THSD7A expression in human cancer [J]. Genes Chromosomes Cancer, 2017, 56(4): 1-55.
[22]
Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy [J].J Clini Invest, 2016, 126(7): 2519-2532.
[1] 蚁淳, 袁冬生, 熊学军. 系统免疫炎症指数与骨密度降低和骨质疏松的关联[J/OL]. 中华关节外科杂志(电子版), 2024, 18(05): 609-617.
[2] 李志文, 李远志, 李华, 方志远. 糖皮质激素治疗膝骨关节炎疗效的网状Meta分析[J/OL]. 中华关节外科杂志(电子版), 2024, 18(04): 484-496.
[3] 吴姗姗, 潘裕民, 刘晋, 张劲松, 乔莉. 睡眠呼吸暂停综合征患者静脉血栓栓塞症发生率的Meta分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 312-317.
[4] 程鹏, 杨道鸿, 邓文君, 钟宇琼, 胡晓雪, 黄小银, 周道扬. 纤维蛋白原治疗创伤性凝血病有效性和安全性的Meta分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(03): 225-231.
[5] 沈皓, 张驰, 韩旻轩, 陆晓庆, 周愉, 周莉丽. 骨皮质切开术对正畸治疗牙根吸收影响的Meta分析[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(03): 175-184.
[6] 郭仁凯, 武慧铭, 李辉宇. 机器人辅助全系膜切除术治疗右半结肠癌有效性和安全性的Meta分析及试验序贯分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 234-240.
[7] 朱俊佳, 孙琦, 徐文龙, 陆天宇, 冯强, 储涛, 邢春根, 高春冬, 俞一峰, 赵振国. 永久性结肠造口预防性补片置入对预防造口旁疝价值的Meta分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(03): 336-342.
[8] 王招荐, 曹桢, 郭小双, 靳小雷, 刘子文. 加速康复外科理念应用于腹壁重建手术的系统评价及Meta分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(03): 343-350.
[9] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[10] 龚财芳, 赵俊宇, 游川. 围手术期肠内营养在肝癌肝切除患者中有效性及安全性的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 551-556.
[11] 郁凯, 曾保起, 杨剑, 杨杰, 张殿英, 孙凤. 全关节镜与切开手术治疗肩袖撕裂疗效比较的系统综述与Meta分析[J/OL]. 中华肩肘外科电子杂志, 2024, 12(03): 238-245.
[12] 施麟宵, 洪兰兰, 阳柳, 芶碧珍, 刘畅, 吴欣. 钠-葡萄糖协同转运蛋白2 抑制剂治疗原发性膜性肾病的疗效及其对Th1/Th2 的影响[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 261-267.
[13] 张勤灵, 王盼飞, 赵倩文. 尿β2-微球蛋白在原发性膜性肾病预后评估中的作用[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 195-200.
[14] 王芳, 刘达, 左智炜, 盛金平, 陈庭进, 蒋锐. 定量CT与双能X线骨密度仪对骨质疏松诊断效能比较的Meta分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 363-371.
[15] 周倩妹, 王宪娥, 徐筱, 老慧琳, 赵欣悦, 胡菁颖. 多元化系统护理对老年人群牙周健康指标影响的系统评价[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 500-506.
阅读次数
全文


摘要